| Cell line name | GTL16R3 |
|---|---|
| Synonyms | GTL16 R3 |
| Accession | CVCL_VS68 |
| Resource Identification Initiative | To cite this cell line use: GTL16R3 (RRID:CVCL_VS68) |
| Comments | Population: Japanese. Selected for resistance to: ChEBI; CHEBI:91425; 2-[4-[3-(6-quinolinylmethyl)-5-triazolo[4,5-b]pyrazinyl]-1-pyrazolyl]ethanol (PF-04217903). Omics: SNP array analysis. Omics: Transcriptome analysis. |
| Sequence variations | Gene fusion; HGNC; 1097; BRAF + HGNC; 30646; SND1; Name(s)=SND1-BRAF (PubMed=22745804).Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line). |
| Disease | Gastric adenocarcinoma (NCIt: C4004) Derived from metastatic site: Liver. |
| Species of origin | Homo sapiens (Human)
(NCBI Taxonomy: 9606)
|
| Hierarchy | Parent: CVCL_7668 (GTL-16) |
| Sex of cell | Female |
| Age at sampling | 62Y |
| Category | Cancer cell line |
| Publications | PubMed=22745804; DOI=10.1371/journal.pone.0039653 |
| Cross-references | |
| Gene expression databases | GEO; GSM686017
GEO; GSM686037 GEO; GSM686038 |
| Other | Wikidata; Q93935415 |
| Polymorphism and mutation databases | Progenetix; CVCL_VS68 |
| Entry history | |
| Entry creation | 25-Feb-2019 |
| Last entry update | 20-May-2021 |
| Version number | 7 |